- Amendments to the Claims -

Amend claims 1, 4, 12 and 25 as follows:

1. (Currently amended) A compound of Formula (1.0.0):



(1.0.0)

— wherein —

-j is 1;

-k is 0 or 1

-m is 1, 2, or 3;

-n is 1 or 2;

-W^1 and W^2 are independently —O— ; or —$S(=O)_t$— , where t is 0, 1, or 2;

-Y is =$C(R^1{}_a)$—, where $R^1{}_a$ has the same meaning as defined below;

— where —

--$R^1{}_a$ is a member selected from the group consisting of –H; –F; –Cl; –CN; –NO_2; –(C_1-C_4) alkyl; –(C_2-C_4) alkynyl; fluorinated–(C_1 -C_3) alkyl; fluorinated-(C_1 -C_3) alkoxy; -OR^{16}; and –$C(=O)NR^{22}{}_aR^{22}{}_b$;

— where —

---$R^{22}{}_a$ and $R^{22}{}_b$ are each independently –H; –CH_3; –CH_2CH_3; –$CH_2CH_2CH_3$; -$CH_2(CH_3)_2$; –$CH_2CH_2CH_2CH_3$; –$CH(CH_3)CH_2CH_3$; –$CH_2CH(CH_3)_2$; –$C(CH_3)_3$; cyclopropyl; cyclobutyl; or cyclopentyl;

-R^A and R^B are each a member independently selected from the group consisting of –H; –F; –CF_3; –(C_1-C_4) alkyl; –(C_3-C_7) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R^{10};

— where —

--R^{10} is a member selected from the group consisting of phenyl; pyridyl; –F; -Cl; -CF_3; oxo (=O); –OR^{16}; –NO_2; –CN; –$C(=O)OR^{16}$; -O-$C(=O)R^{16}$; –$C(=O)NR^{16}R^{17}$; -O-$C(=O)NR^{16}R^{17}$;

$-NR^{16}R^{17}$; $-NR^{16}C(=O)R^{17}$; $-NR^{16}C(=O)OR^{17}$; $-NR^{16}S(=O)_2R^{17}$; and $-S(=O)_2NR^{16}R^{17}$; where said phenyl or pyridyl is substituted by 0 to 3 R^{11};

— where —

---R^{11} is –F; –Cl; $-CF_3$; –CN; $-NO_2$; –OH; $-(C_1-C_3)$ alkoxy; $-(C_1-C_3)$ alkyl; or $-NR^{16}R^{17}$;

— and —

----R^{16} and R^{17} are each a member independently selected from the group consisting of –H; $-(C_1-C_4)$ alkyl; $-(C_2-C_4)$ alkenyl; $-(C_3-C_6)$ cycloalkyl; phenyl; benzyl; and pyridyl; wherein said alkyl, alkenyl, cycloalkyl, phenyl, benzyl, or pyridyl is substituted by 0 to 3 substituents selected from the group consisting of –F, –Cl, $-CF_3$, –CN, and $-(C_1-C_3)$ alkyl;

-R^C and R^D have the same meaning as defined above for R^A and R^B except that one of them must be –H, and they are selected independently of each other and of R^A and R^B;

-R^1 and R^2 may individually or together appear on any ring or rings comprising a meaning of the moiety J² as defined below; and R^1 and R^2 are each a member independently selected from the group consisting of –H; –F; –Cl; –CN; $-NO_2$; $-(C_1-C_4)$ alkyl; $-(C_2-C_4)$ alkynyl; fluorinated–(C_1-C_3) alkyl; $-OR^{16}$; and $-C(=O)NR^{22}{}_aR^{22}{}_b$; where R^{16}, $R^{22}{}_a$, and $R^{22}{}_b$ have the same meanings as defined above;

-R^3 is –H; $-(C_1-C_3)$ alkyl; phenyl; benzyl; or $-OR^{16}$, where R^{16} has the same meaning as defined above;

-R^4 may appear on any ring or rings comprising a meaning of the moiety J¹ as defined below; and R^4 are each a member independently selected from the group consisting of

— the following: —

-*(a)* –H; –F; –Cl; $-(C_2-C_4)$ alkynyl; $-R^{16}$; $-OR^{16}$; $-S(=O)_pR^{16}$; $-C(=O)R^{16}$; $-C(=O)OR^{16}$; $-OC(=O)R^{16}$; –CN; $-NO_2$; $-C(=O)NR^{16}R^{17}$; $-OC(=O)NR^{16}R^{17}$; $-NR^{22}{}_aC(=O)NR^{16}R^{17}$; $-NR^{22}{}_aC(=NR^{12})NR^{16}R^{17}$; $-NR^{22}{}_aC(=NCN)NR^{16}R^{17}$; $-NR^{22}{}_aC(=N-NO_2)NR^{16}R^{17}$; $-C(=NR^{22}{}_a)NR^{16}R^{17}$; $-CH_2C(=NR^{22}{}_a)NR^{16}R^{17}$; $-OC(=NR^{22}{}_a)NR^{16}R^{17}$; $-OC(=N-NO_2)NR^{16}R^{17}$; $-NR^{16}R^{17}$; $-CH_2NR^{16}R^{17}$; $-NR^{22}{}_aC(=O)R^{16}$; $-NR^{22}{}_aC(=O)OR^{16}$; $=NOR^{16}$; $-NR^{22}{}_aS(=O)_pR^{17}$ $-S(=O)_pNR^{16}R^{17}$; and $-CH_2C(=NR^{22}{}_a)NR^{16}R^{17}$;

— where —

--p is 0, 1, or 2; and $R^{22}{}_a$, R^{16}, and R^{17} have the same meanings as defined above;

-*(b)* $-(C_1-C_4)$ alkyl; and $-(C_1-C_4)$ alkoxy in the case where R^4 has the meaning of $-OR^{16}$ under *(a)* above and R^{16} is defined as $-(C_1-C_4)$ alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents –F or –Cl; or 0 or 1 substituent (C_1-C_2) alkoxycarbonyl–; (C_1-C_2) alkylcarbonyl–; or (C_1-C_2) alkylcarbonyloxy–; provided R^{16} and R^{17} in the definition of R^4 is not pyridyl;

—and—

~~(c)~~

--R^{14} is a member selected from the group consisting of $-(C_1-C_4)$ alkyl; $-(C_3-C_7)$ cycloalkyl; phenyl; benzyl; where said alkyl, cycloalkyl, phenyl and benzyl are substituted by 0, 1, or 2 substituents –F, –Cl, $-CH_3$, $-OR^{16}$, $-NO_2$, –CN, or $-NR^{16}R^{17}$; and said R^{14} group further consists of –F; -Cl; $-CF_3$; oxo (=O); $-OR^{16}$; $-NO_2$; –CN; $-C(=O)OR^{16}$; $-O-C(=O)R^{16}$; $-C(=O)NR^{16}R^{17}$; $-O-C(=O)NR^{16}R^{17}$; $-NR^{16}R^{17}$; $-NR^{16}C(=O)R^{17}$; $-NR^{16}C(=O)OR^{17}$; $-NR^{16}S(=O)_2R^{17}$; or $-S(=O)_2NR^{16}R^{17}$; where R^{16} and R^{17} have the same meanings as defined above; provided that said R^{16} and R^{17} in the definition of R^{14} is not pyridyl;

----R^{12} is a member independently selected from the group consisting of –F; –Cl; $-CO_2R^{18}$; $-OR^{16}$; –CN; $-C(=O)NR^{18}R^{19}$; $-NR^{18}R^{19}$; $-NR^{18}C(=O)R^{19}$; $-NR^{18}C(=O)OR^{19}$; $-NR^{18}S(=O)_pR^{19}$; $-S(=O)_pNR^{18}R^{19}$, where p is 1 or 2; $-(C_1-C_4)$ alkyl; and $-(C_1-C_4)$ alkoxy in the case where R^{12} has the meaning of $-OR^{16}$ above and R^{16} is defined as $-(C_1-C_4)$ alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents independently selected from –F; –Cl; $-(C_1-C_2)$ alkoxycarbonyl; $-(C_1-C_2)$ alkylcarbonyl; and $-(C_1-C_2)$ alkylcarbonyloxy; where R^{16} has the same meaning as defined above; and

— where —

-----R^{18} and R^{19} are independently selected from the group consisting of –H; $-(C_1-C_4)$ alkyl; and phenyl; where said alkyl or phenyl is substituted by 0-3 of –F; or –Cl;

— or in the case where J' is phenyl —

-(d) R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1) through (1.3.3) and (1.3.5) through (1.3.15):


(1.3.1)


(1.3.2)


(1.3.3)


(1.3.5)


(1.3.6)


(1.3.7)


(1.3.8)


(1.3.9)


(1.3.10)



(1.3.11) (1.3.12) (1.3.13) (1.3.14) (1.3.15)

— wherein —

--R^{20} and R^{21} are each a member independently selected from the group consisting of –H; –F; –Cl; $-CH_3$; $-CH_2F$; $-CHF_2$; $-CF_3$; $-OCH_3$; and $-OCF_3$;

--R^{23} and R^{24} are each independently –H; $-CH_3$; $-OCH_3$; $-CH_2CH_3$; $-OCH_2CH_3$; $-CH_2CH_2CH_3$; $-CH_2(CH_3)_2$; $-CH_2CH_2CH_2CH_3$; $-CH(CH_3)CH_2CH_3$; $-CH_2CH(CH_3)_2$; $-C(CH_3)_3$; or absent, in which case the dashed line – – – – represents a double bond;

-$\mathbb{J}^1$ is a moiety comprising a saturated or unsaturated carbon ring system that is a 6-membered monocyclic ring;

-$\mathbb{J}^2$ is a moiety comprising a saturated or unsaturated carbon ring system that is a 6-membered monocyclic ring;

-$\mathbb{D}$ is a member independently selected from the group consisting of

— the following —

-*(a)* the group consisting of partial Formulas (1.1.1) through (1.1.5):



(1.1.1) (1.1.2) (1.1.3) (1.1.4)



(1.1.5)

— wherein —

--"*" indicates the point of attachment of each partial Formula (1.1.1) through (1.1.5) to the remaining portion of Formula (1.0.0);

--q is 1, 2, or 3, provided that where q is 2 or 3, R^9 has the meaning of –H in at least one instance, or two instances, respectively;

--v 0 or 1;

--W^3 is —O—; —N(R^9)—, where R^9 has the same meaning as defined below; or —OC(=O)—;

--R^7 is a member independently selected from the group consisting of

— the following: —

--*(1)* –H;

--*(2)* –(C_1-C_6) alkyl; –(C_2-C_6) alkenyl; or –(C_2-C_6) alkynyl; where said alkyl, alkenyl or alkynyl is substituted by 0 to 3 substituents R^{10}, where R^{10} has the same meaning as defined above; provided that R^{10} in the meaning of R^7 --(2) is not pyridyl;

--*(3)* –(CH_2)$_u$-(C_3-C_7) cycloalkyl where u is 0, 1 or 2; and further where said (C_3-C_7) cycloalkyl is substituted by 0 to 3 substituents R^{10} where R^{10} has the same meaning as defined above; provided that R^{10} in the meaning of R^7 --(3) is not pyridyl;

— and —

--*(4)* phenyl or benzyl, where said phenyl or benzyl is independently substituted by 0 to 3 substituents R^{10} where R^{10} has the same meaning as defined above; provided that R^{10} in the meaning of R^7 --(4) is not pyridyl;

--R^8 is phenyl;

— where —

said phenyl is optionally ~~by a~~ substituent R^{14};

--R^9 is a member selected from the group consisting of –H; –(C_1-C_4) alkyl; -(C_3-C_7) cycloalkyl; phenyl; benzyl; –C(=O)OR^{16}; –C(=O)R^{16}; –OR^{16}; –(C_1-C_2) alkyl–OR^{16}; and –(C_1-C_2) alkyl–C(=O)OR^{16}; provided that R^{16} in the definition of R^9 is not pyridyl;

— and D is further selected from —

-(b) a moiety comprising a member selected from the group consisting of -O-P(=O)(OH)$_2$ (phosphoric); –PH(=O)OH (phosphinic); -P(=O)(OH)$_2$ (phosphonic); -[P(=O)(OH)–O(C_1-C_4) alkyl] (alkylphosphono); -P(=O)(OH)-O(C_1-C_4) alkyl) (alkylphosphinyl); –P(=O)(OH)NH_2 (phosphoramido); -P(=O)(OH)NH(C_1-C_4) alkyl and -P(=O)(OH)NHR^{25} (substituted phosphoramido); -O-S(=O)$_2$OH (sulfuric); –S(=O)$_2$OH (sulfonic); –S(=O)$_2$NHR^{26} or -NHS(=O)$_2$$R^{26}$ (sulfonamido) where R^{26} is –CH_3, –CF_3, or *o*-toluyl; and acylsulfonamido selected from the group consisting of -C(=O)NHS(=O)$_2$$R^{25}$; -C(=O)NHS(=O)$_2$$NH_2$; -C(=O)NHS(=O)$_2$($C_1$-$C_4$) alkyl; -C(=O)NHS(=O)$_2$NH($C_1$-$C_4$) alkyl; -C(=O)NHS(=O)$_2$N[($C_1$-$C_4$) alkyl]$_2$; -S(=O)$_2$NHC(=O)($C_1$-$C_4$) alkyl; –S(=O)$_2$NHC(=O)$NH_2$; -S(=O)$_2$NHC(=O)NH($C_1$-$C_4$) alkyl; -S(=O)$_2$NHC(=O)N[($C_1$-$C_4$) alkyl]$_2$; –S(=O)$_2$NHC(=O)$R^{25}$;

$-S(=O)_2NHCN$; $-S(=O)_2NHC(=S)NH_2$; $-S(=O)_2NHC(=S)NH(C_1\text{-}C_4)$ alkyl; $-S(=O)_2NHC(=S)N[(C_1\text{-}C_4)\text{ alkyl}]_2$; and $-S(=O)_2NHS(=O)_2R^{25}$;

— where —

$--R^{25}$ is –H; $-(C_1\text{-}C_4)$ alkyl; phenyl; or $-OR^{18}$, where R^{18} has the same meaning as defined above;

— or —

a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Canceled)

4. (Currently amended) A compound according to Claim 1 wherein the right-hand terminus thereof, where m is 1, is represented by partial Formula (1.0.5):



(1.0.5)

where " * " is a symbol representing the point of attachment of the moiety of partial Formula (1.0.5) to the remaining portion of a compound of Formula (1.0.0); where R^A and R^B are both -H, or one is –H and the other is $-CH_3$, or both are $-CH_3$; R^1 is –H, $-OCH_3$, or 2'–F; R^2 is -H; and the moieties J^2 and D are selected such that, said moiety of partial Formula (1.0.5) is a member selected from the group consisting of partial Formulas (1.5.1), (1.5.3), (1.5.5) through (1.5.8), (1.5.10) through (1.5.12), (1.5.17 through (1.5.22), (1.5.26), (1.5.27) and (1.5.32):



(1.5.1)



(1.5.3)



(1.5.5)



(1.5.6)





(1.5.7)



(1.5.8)





(1.5.10)

(1.5.11)

(1.5.12)





(1.5.17)

(1.5.18)







(1.5.19)

(1.5.20)

(1.5.21)



(1.5.22)

~~(1.5.23)~~

~~(1.5.24)~~





(1.5.26)

(1.5.27)

~~(1.5.28)~~

~~(1.5.29)~~



(1.5.32)

~~(1.5.45)~~

– wherein –

--"*" indicates the point of attachment of each said group of partial Formula (1.0.5) represented by partial Formulas (1.5.1), (1.5.3), (1.5.5) through (1.5.8), (1.5.10) through (1.5.12), (1.5.17 through (1.5.24), (1.5.26), (1.5.27 and (1.5.32) to the remaining portion of Formula (1.0.0).

5. (Canceled)

6. (Canceled)

7. (Previously presented) A compound according to Claim 1 wherein J' and the substituents R^4, R^5, and R^6 are selected in such a way that a portion of the left-hand terminus of a compound of Claim 1 is a member selected from the group consisting of partial Formulas (2.0.11), (2.0.12), (2.0.14) - (2.0.20), (2.0.40), (2.0.60), (2.0.63) and (2.0.66) - (2.0.70):



(2.0.11)



(2.0.12)



(2.0.14)



(2.0.15)



(2.0.16)



(2.0.17)



(2.0.18)



(2.0.19)



(2.0.20)



(2.0.40)



(2.0.63)



(2.0.66)



(2.0.67)



(2.0.68)



(2.0.69)



(2.0.70)

8. (Canceled)

9. (Previously presented) A compound according to Claim 1 wherein J^2 and the substituents R^1 and R^2 are selected in such a way that a portion of the right-hand terminus of a compound of Claim 1 is a member selected from the group consisting of partial Formulas (2.5.1) to (2.5.7), (2.5.10), (2.5.14), (2.5.24) to (2.5.26), (2.5.34), (2.5.37 to (2.5.41) and (2.5.50):



(2.5.1)



(2.5.2)



(2.5.3)



(2.5.4)



(2.5.5)



(2.5.6)



(2.5.7)



(2.5.10)



(2.5.14)



(2.5.24)



(2.5.25)



(2.5.26)



(2.5.34)



(2.5.37)



(2.5.38)



(2.5.39)



(2.5.40)



(2.5.41)



(2.5.50)

10. (Original) A compound according to Claim 1 wherein Y is $=C(R^1_a)-$ where R^1_a is –H; -F; -Cl; $-CH_3$; or $-OCH_3$.

11. (Original) A compound according to Claim 10 wherein $R^1{}_a$ is –H; or -F.

12. (Previously presented) A compound according to Claim 1 wherein where m is 1 or 2, and n is 1; ◆ R^A and R^B are –H, $–CF_3$, or -(C_1-C_6) alkyl substituted by 0 or 1 of –F, -Cl, $–CF_3$, –CN, $-NH_2$, or $-C(=O)NH_2$; ◆ one of R^C and R^D is -H, and the other is –H, -(C_1-C_4) alkyl, or phenyl, each substituted by 0 or 1 of -F, -Cl, or –CN; ◆ W^1 is –O– or –S–; ◆ W^2 is –O–; ◆ Y is $= C(R^1{}_a)—$ where $R^1{}_a$ is -H, –F, –Cl, -CN, $-CH_3$, or $-OCH_3$; ◆ R^1 and R^2 are -H, –F, –Cl, –CN, $-NO_2$, -OH, $-CH_3$, $-OCH_3$, $–OCHF_2$, or $-OCF_3$; ◆ R^3 is -H or $-CH_3$; ◆ R^4 is –H, –F, –CN, $–NO_2$, -OH, $-CH_3$, or $–OCH_3$; ◆ J^1 is phenyl; ◆ R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.1) where R^{20} and R^{21} are –H or $–CH_3$; or a moiety of partial Formula (1.3.11), (1.3.12), or (1.3.15) where R^{23} and R^{24} are absent or are –H, or $-CH_3$; ◆ J^2 is phenyl, norbornanyl or cyclohexyl; ◆ and D is $-C(=O)OR^7$ where R^7 is -H or $–CH_3$; or $–C(=O)NH_2$.

13. (Previously presented) A compound according to Claim 12 wherein R^A and R^B are both $–CH_3$, or one is $–CH_3$ and the other is $–CH(CH_3)_2$ or $–C(CH_3)_3$, or one is –H and the other is $–CH_3$ or $–CF_3$; ◆ one of R^C and R^D is –H and the other is –H or $–CH_3$; W^1 is –O–; ◆ Y is $= C(R^1{}_a)—$ where $R^1{}_a$ is –H, –F, or -Cl; ◆ R^1 and R^2 are –H, -F, or Cl; ◆ R^3 is –H; ◆ R^4 is –H; ◆ R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.1) or (1.3.11) where R^{23} and R^{24} are both absent; ◆ J^2 is phenyl or cyclohexyl; ◆ and D is $-C(=O)OR^7$ where R^7 is –H, $–CH_3$ or $–C(=O)NH_2$.

14. (Previously presented) A compound according to Claim 13 wherein R^A and R^B are both $–CH_3$; ◆ one of R^C and R^D is -H and the other is –H or $-CH_3$; ◆ Y is $= C(R^1{}_a)—$ where $R^1{}_a$ is –H, –F, or –Cl; ◆ R^1 and R^2 are –H, -F, or Cl; ◆ R^3 is -H; ◆ R^4 is –H; ◆ R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.11) where R^{23} and R^{24} are both absent; ◆ J^2 is phenyl; ◆ and D is $-C(=O)OR^7$ where R^7 is –H or $–CH_3$ or $–C(=O)NH_2$.

15. (Original) A compound according to Claim 14 wherein R^A and R^B are both $–CH_3$; ◆ R^C and R^D are both –H; ◆ Y is $= C(R^1{}_a)—$ where $R^1{}_a$ is –H; ◆ and one of R^1 and R^2 is –H and the other is –F.

16. (Original) A compound according to Claim 14 wherein Y is $= C(R^1{}_a)—$ where $R^1{}_a$ is –F; ◆ and R^1 and R^2 are both –H.

17. (Previously presented) A compound according to Claim 13 wherein R^A and R^B are both $–CH_3$; ◆ one of R^C and R^D is -H and the other is –H or $-CH_3$; ◆ Y is $= C(R^1{}_a)—$ where

$R^1{}_a$ is –H, –F, or –Cl; ◆ R^1 and R^2 are –H, -F, or Cl; ◆ R^3 is -H; ◆ R^4 is –H; R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.1) where R^{20} and R^{21} are both –H; ◆ J^2 is phenyl; ◆ and D is -C(=O)OR^7 where R^7 is –H or $–CH_3$ or -C(=O)NH_2.

18. (Original) A compound according to Claim 17 wherein R^A and R^B are both $–CH_3$; ◆ R^C and R^D are both –H; ◆ Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –H; ◆ and one of R^1 and R^2 is –H and the other is –F.

19. (Original) A compound according to Claim 18 wherein Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –F; ◆ and R^1 and R^2 are both –H.

20. (Previously presented) A compound according to Claim 1 wherein D is -P(=O)(OH)NHR^{25}; $–S(=O)_2NHR^{26}$ or -$NHS(=O)_2R^{26}$ where R^{26} is $-CH_3$, $–CF_3$, or *o*-toluyl; or -C(=O)$NHS(=O)_2R^{25}$.

21. (Previously presented) A compound according to Claim 1 wherein R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1), (1.3.11), (1.3.12), and (1.3.15):



(1.3.1)



(1.3.11)



(1.3.12)



(1.3.15).

22. (Original) A compound according to Claim 21 wherein R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (2.1.1), (2.1.4) through (2.1.6), (2.1.11), and (2.1.16) through (2.1.20):

(2.1.1)



(2.1.4)



(2.1.5)



(2.1.6)



(2.1.11)



(2.1.16) (2.1.17) (2.1.18) (2.1.19) (2.1.20)

wherein the dashed line – – – – in partial Formulas (2.1.18), (2.1.19), and (2.1.20) represents a double bond where no oxygen atom is attached to the corresponding nitrogen atom, and represents a single bond where an oxygen atom is attached to said corresponding nitrogen atom.

23. (Previously presented) A compound according to Claim 1 wherein the J^2 moiety is cyclohexenyl.

24. (Canceled)

25. (Currently amended) A compound according to Claim 1 wherein said compound is a member selected from the group consisting of the following:

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-acetic acid ~~of Formula (5.5.1)~~;

(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid ~~of Formula (5.5.2)~~;

~~(±)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.3);~~

(±)-2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.4)~~;

(±)-2-[3-Fluoro-4-({[2-(3-cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.5)~~;

(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid ~~of Formula (5.5.6)~~;

~~(±)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.7);~~

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid ~~of Formula (5.5.8)~~;

(S)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid ~~of Formula (5.5.9)~~;

~~(R)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.10);~~

(R)-2-[3-Fluoro-4-({[2-(3-cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.11)~~;

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid ~~of Formula (5.5.12)~~;

~~(R)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.13);~~

(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide ~~of Formula (5.5.14)~~;

~~(R)-2-(Benzo[2,1,3]oxadiazol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide of Formula (5.5.15);~~

~~(R)-2-(Benzo[2,1,3]thiadiazol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide of Formula (5.5.16);~~

(R)-N-[4-(1-Carbamoyl-ethoxy)-2-fluoro-benzyl]-2-(3-cyano-phenoxy)-nicotinamide ~~of Formula (5.5.17)~~;

(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-5-fluoro-nicotinamide ~~of Formula (5.5.18)~~;

[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid ~~of Formula (5.5.29)~~;

~~[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.30);~~

~~(±)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.31);~~

~~(±)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.32);~~

(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid ~~of Formula (5.5.33)~~;

(±)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid ~~of Formula (5.5.34)~~;

(±)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid ~~of Formula (5.5.35)~~;

~~(±)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.36);~~

~~(R)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.37);~~

~~(R)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.38);~~

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid ~~of Formula (5.5.39)~~;

(R)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid ~~of Formula (5.5.40)~~;

(R)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid ~~of Formula (5.5.41)~~;

~~(R)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.42);~~

~~[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.43);~~

~~[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.44);~~

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid ~~of Formula (5.5.45)~~;

[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid ~~of Formula (5.5.46)~~;

[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid ~~of Formula (5.5.47)~~;

~~[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.48);~~

~~(±)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.49);~~

~~(±)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.50);~~

(±)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid ~~of Formula (5.5.); of Formula (5.5.51)~~;

(±)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid ~~of Formula (5.5.52)~~;

~~(±)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.53);~~

~~(R)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.54);~~

~~(R)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.55);~~

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid ~~of Formula (5.5.56)~~;

(R)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid ~~of Formula (5.5.57)~~;

(R)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid ~~of Formula (5.5.58)~~;

~~(R)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.59);~~

~~2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.60);~~

~~2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.61);~~

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid ~~of Formula (5.5.62)~~;

2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid ~~of Formula (5.5.63)~~;

2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid ~~of Formula (5.5.64)~~;

~~2-Methyl-2-[4-({[2-(2-methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.65);~~

~~2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-2-methyl-propionic acid of Formula (5.5.83);~~

~~2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.84);~~

~~2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.85);~~

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid ~~of Formula (5.5.86)~~;

2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-2-methyl-propionic acid ~~of Formula (5.5.87)~~;

2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid ~~of Formula (5.5.88)~~;

~~[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.89);~~

(±)-2-[3-Fluoro-4-({[2-(3-nitro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.94)~~;

~~[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.97);~~

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid ~~of Formula (5.5.98)~~;

[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid ~~of Formula (5.5.99)~~;

(R)-2-[4-({[2-(3-Methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.100)~~;

(R)-2-[3-Fluoro-4-({[2-(3-methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.101)~~;

(R)-2-[3-Fluoro-4-({[5-fluoro-2-(3-methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.102)~~;

(R)-2-[4-({[2-(3-Nitro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.103)~~;

(R)-2-[4-({[2-(3-Chloro-4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.104)~~;

(R)-2-[4-({[2-(3,4-Difluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.105)~~;

(R)-2-[4-({[2-(2,3-Dihydro-benzofuran-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.106)~~; and

(R)-2-[4-({[2-(2,3-Dihydro-benzofuran-6-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid ~~of Formula (5.5.107)~~.

26. - 30. (Canceled)

31. (Previously presented) A method of treating a disease, disorder or condition mediated by the PDE4 isozyme in a mammal, said method comprising administering to said mammal in need of such mediation, a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

32. (Previously presented) A method of claim 31 wherein said PDE4 isozyme is the PDE4-D subtype isozyme.

33. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is atopic asthma; non-atopic asthma; allergic asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by pathophysiologic disturbances; extrinsic asthma caused by environmental factors; essential asthma of unknown or inapparent cause; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial, fungal, protozoal or viral infection; non-allergic asthma; incipient asthma; or wheezy infant syndrome.

34. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; emphysema; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease; adult respiratory distress syndrome; or exacerbation of airways hyper-reactivity consequent to other drug therapy.

35. (Previously presented) A method of claim 34 wherein said chronic obstructive pulmonary disease is characterized by irreversible, progressive airways obstruction.

36. (Previously presented) A method of claim 34 wherein said pneumonconiosis is aluminosis; bauxite workers' disease; anthracosis; miners' disease; asbestosis; steam-fitters' asthma; chalicosis; flint disease; ptilosis caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis; grinders' disease; byssinosis; cotton-dust asthma; or talc pneumoconiosis.

37. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is bronchitis; acute bronchitis; chronic bronchitis; acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis; productive bronchitis; staphylococcus bronchitis; streptococcal bronchitis; or vesicular bronchitis.

38. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is bronchiectasis; cylindric bronchiectasis; sacculated bronchiectasis; fusiform brochiectasis; capillary bronchiectasis; cystic bronchiectasis; dry bronchiectasis or follicular bronchiectasis.

39. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is seasonal allergic rhinitis; perennial allergic rhinitis; sinusitis; purulent sinusitis; nonpurulent sinusitis; acute sinusitis; chronic sinusitis; ethmoid sinusitis; frontal sinusitis; or sphenoid sinusitis.

40. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is regulated by the activation and degranulation of eosinophils.

41. (Previously presented) A compound of claim 1 which is (R)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid.